Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers.
The aim of this study was to formulate and optimize gliclazide-loaded Eudragit nanoparticles (Eudragit L100 and Eudragit RS) as a sustained release carrier with enhanced efficacy. Eudragit L 100 nanoparticles (ELNP) were prepared by controlled precipitation method whereas Eudragit RSPO nanoparticles (ERSNP) were prepared by solvent evaporation method. The influence of various formulation factors (stirring speed, drug:polymer ratio, homogenization, and addition of surfactants) on particle size, drug loading, and encapsulation efficiency were investigated. The developed Eudragit nanoparticles (L100 and RS) showed high drug loading and encapsulation efficiencies with nanosize. Mean particle size altered by changing the drug:polymer ratio and stirring speed. Addition of surfactants showed a promise to increase drug loading, encapsulation efficiency, and decreased particle size of ELNP as well as ERSNP. Dissolution study revealed sustained release of gliclazide from Eudragit L100 as well as Eudragit RSPO NP. SEM study revealed spherical morphology of the developed Eudragit (L100 and RS) NP. FT-IR and DSC studies showed no interaction of gliclazide with polymers. Stability studies revealed that the gliclazide-loaded nanoparticles were stable at the end of 6 months. Developed Eudragit NPs revealed a decreased t(min) (ELNP), and enhanced bioavailability and sustained activity (ELNP and ERSNP) and hence superior activity as compared to plain gliclazide in streptozotocin induced diabetic rat model and glucose-loaded diabetic rat model. The developed Eudragit (L100 and RSPO) NP could reduce dose frequency, decrease side effects, and improve patient compliance.
Devarajan
Padma V
PV
Pharmaceutical Division, Institute of Chemical Technology, University of Mumbai, Matunga, Mumbai, India. devrajan@vsnl.net
Sonavane
Ganeshchandra S
GS
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D001786:Blood Glucose / Q000378:metabolism; D000077286:Cetrimonium; D002593:Cetrimonium Compounds / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy; D004339:Drug Compounding / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D004355:Drug Stability; D005907:Gliclazide / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D005951:Glucose Tolerance Test / Q000379:methods; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D015394:Molecular Structure; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011109:Polymethacrylic Acids / Q000737:chemistry*; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry
D001786:Blood Glucose; D002593:Cetrimonium Compounds; D003692:Delayed-Action Preparations; C496966:Eudragit RSPO; D007004:Hypoglycemic Agents; D011109:Polymethacrylic Acids; D013501:Surface-Active Agents; C038300:methylmethacrylate-methacrylic acid copolymer; D005907:Gliclazide; D000077286:Cetrimonium